.
RETA financial statements
* Numbers in millions
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
Capitalization * |
495 | 694 | 2 134 | 5 902 | 3 750 | 1 190 |
EV * |
410 | 583 | 1 875 | 5 392 | 2 933 | 2 933 |
Stock price $ |
24.99 | 28.98 | 77.02 | 194.04 | 103.59 | 32.87 |
Number of shares * |
20 | 24 | 28 | 30 | 36 | 36 |
EPS |
-0,31 | -1,99 | -2,91 | -9,54 | -6,84 | -6,84 |
Revenue * |
50 | 48 | 54 | 27 | 9 | 9 |
Net income * |
-6 | -48 | -81 | -290 | -248 | -248 |
Operating profit * |
-7 | -47 | -77 | -285 | -226 | -226 |
Total liabilities * |
304 | 282 | 330 | 426 | 440 | 440 |
Net debt * |
-85 | -110 | -259 | -509 | -818 | -818 |
Total assets * |
89 | 135 | 345 | 682 | 858 | 858 |
Equity * |
-215 | -147 | 15 | 257 | 417 | 417 |
Cash and investments * |
85 | 130 | 338 | 664 | 818 | 818 |
Over the past 10 years, the maximum capitalization of Reata Pharmaceuticals, Inc. is 5 902, the minimum is 495. Maximum net income 0, Minimum net income -290. The maximum price of RETA shares is 194.04, the minimum price is 24.99.
.
RETA valuation
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
P/E |
-79,53 | -14,55 | -26,49 | -20,34 | -15,14 | -4,80 |
P/B |
-2,30 | -4,72 | 140,75 | 22,98 | 8,98 | 2,85 |
P/S |
9,93 | 14,43 | 39,81 | 222,56 | 415,83 | 131,95 |
E/P |
-1% | -7% | -4% | -5% | -7% | -21% |
P/FCF |
-25,27 | -8,30 | -25,26 | -23,25 | -11,60 | -3,68 |
.
RETA profitability
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
ROE |
3% | 32% | -531% | -113% | -59% | |
ROA |
-7% | -35% | -23% | -43% | -29% | |
ROIC |
-23% | -53% | -27% | -58% | -31% |